Fiscal first quarter worldwide Impella^® revenue totaled $38.7 million, up 12% compared to revenue of $34.7 million during the same period of the prior year. U.S. Impella revenue grew 7% to $35.4 million from $33.0 million in the prior year with U.S. Impella patient usage up 12%.

An additional 27 hospitals purchased Impella 2.5 during the quarter, bringing the total to 775 customer sites. As part of Abiomed’s continued Impella CP™ launch, an additional 66 hospitals purchased Impella CP, bringing the total number of Impella CP U.S. sites to 172. Impella 2.5 and Impella CP unit inventory at hospitals averaged 2.4 units, equal to the prior sequential quarter.

Gross margin rate for the first quarter of fiscal 2014 was 79.6% compared to 80.8% in the first quarter of fiscal 2013. There were 191 Impella AIC consoles placed during the quarter compared to 163 in the same period of the prior year.

Income/(loss) from operations for the first quarter fiscal 2014 was a loss of $1.3 million, compared to a gain of $3.6 million in the prior year period. Compared to the prior year, the loss included $2.6 million of incremental legal expenses related to the Department of Justice subpoena, shareholder lawsuit and derivative action, $1.2 million of higher stock compensation expense and $0.6 million of incremental expense for the medical device tax.

Cash, cash equivalents, short and long-term marketable securities totaled $88 million as of June 30, 2013, which remained unchanged from March 31, 2013. The Company continues to have no debt and a U.S. federal net operating loss carry-forward of approximately $190 million as of March 31, 2013.

Abiomed announced in May the publication of the Protect II Cost Effectiveness Study in American Health & Drug Benefits Journal, demonstrating the cost effectiveness of Impella.

Abiomed also announced that the Netherlands has approved new reimbursement coding and payment for the Impella product. The new coding allows for hospitals to receive funding for the use of the Impella technology in a broad set of clinical indications of heart disease through the process known as Diagnosis Treatment Combinations (Diagnose Behandeling Combinaties; DBCs), similar to the Medicare Diagnosis-Related Group (DRG) system in the United States.

Abiomed also announced in June that the U.S. District Court of Massachusetts dismissed the derivative lawsuit that was filed in February 2013.

There were several Impella-related sessions at the 22nd Annual Meeting of the Japanese Association of CardioVascular Intervention and Therapeutics (CVIT 2013) in Kobe, Japan, which took place July 11-13. Abiomed anticipates Japanese PMDA approval for Impella by the end of the year, with reimbursement to follow within 6 – 12 months.

In July, the 15,000^th U.S. patient was treated with Impella.

The Company has also received written notification that the U.S. Food and Drug Administration (FDA) has reviewed Abiomed’s proposed premarket approval application (PMA) Shell for modular review of the Impella 2.5 System. The FDA has confirmed that the Agency agrees with Abiomed’s proposed Shell and that the company may begin submitting modules.

ASSETS

Current assets:

Cash and cash equivalents

Short-term marketable securities

Accounts receivable, net

Inventories

Prepaid expenses and other current assets

Total current assets

Long-term marketable securities

Property and equipment, net

Goodwill

Other assets

Total assets

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

Accrued expenses

Deferred revenue

Total current liabilities

Long-term deferred tax liability

Other long-term liabilities

Total liabilities

Commitments and contingencies

Stockholders’ equity:

Class B Preferred Stock, $.01 par value

Authorized - 1,000,000 shares; Issued and outstanding - none

Common stock, $.01 par value

Authorized - 100,000,000 shares; Issued - 40,218,485 shares at June 30, 2013 and 39,788,383 shares at March 31, 2013;

Outstanding - 39,012,118 shares at June 30, 2013 and 38,601,384 shares at March 31, 2013

Additional paid in capital

Accumulated deficit

Treasury stock at cost - 1,206,367 shares at June 30, 2013 and 1,186,999 shares at March 31, 2013

Accumulated other comprehensive loss

Total stockholders’ equity

Total liabilities and stockholders’ equity

Revenue:

Product revenue

Funded research and development

Costs and expenses:

Cost of product revenue

Research and development

Selling, general and administrative

Amortization of intangible assets

Income (loss) from operations

Other expense:

Investment income (expense), net

Other expense, net

Income (loss) before income tax provision

Income tax provision

Net income (loss)

Basic net income (loss) per share

Basic weighted average shares outstanding

Diluted net income (loss) per share

Diluted weighted average shares outstanding